Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition by Tsilidis, KK et al.
Oral contraceptive use and reproductive factors and risk
of ovarian cancer in the European Prospective Investigation
into Cancer and Nutrition
KK Tsilidis*,1, NE Allen1, TJ Key1, L Dossus2, A Lukanova2, K Bakken3, E Lund3, A Fournier4,5, K Overvad6,
L Hansen7, A Tjønneland7, V Fedirko8, S Rinaldi8, I Romieu8, F Clavel-Chapelon4,5, P Engel4,5, R Kaaks2,
M Schu¨tze9, A Steffen9, C Bamia10, A Trichopoulou10,11, D Zylis10, G Masala12, V Pala13, R Galasso14, R Tumino15,
C Sacerdote16, HB Bueno-de-Mesquita17,18, FJB van Duijnhoven17, MGM Braem19, NC Onland-Moret19, IT Gram3,
L Rodrı´guez20, N Travier21, M-J Sa´nchez22,23, JM Huerta23,24, E Ardanaz23,25, N Larran˜aga23,26, K Jirstro¨m27,
J Manjer28, A Idahl29,30, N Ohlson31, K-T Khaw32, N Wareham33, T Mouw34, T Norat34 and E Riboli34
1Cancer Epidemiology Unit, Nuff ield Department of Clinical Medicine, University of Oxford, Oxford, UK; 2Division of Cancer Epidemiology,
German Cancer Research Center, Heidelberg, Germany; 3Department of Community Medicine, University of Tromsø, Tromsø, Norway; 4Inserm, Centre
for Research in Epidemiology and Population Health, U1018, Institut Gustave Roussy, F-94805, Villejuif, France; 5Paris South University, UMRS 1018,
F-94805, Villejuif, France; 6Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark; 7Institute of Cancer Epidemiology,
Danish Cancer Society, Copenhagen, Denmark; 8International Agency for Research on Cancer, Lyon, France; 9Department of Epidemiology, German Institute
of Human Nutrition, Potsdam, Germany; 10WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical
Statistics, University of Athens Medical School, Athens, Greece; 11Hellenic Health Foundation, Athens, Greece; 12Molecular and Nutritional Epidemiology Unit,
Cancer Research and Prevention Institute (ISPO), Florence, Italy; 13Nutritional Epidemiology Unit, National Cancer Institute, Milan, Italy; 14Istituto di Ricovero e
Cura a Carattere Scientif ico – Centro di Riferimento Oncologico di Basilicata, Unit of Clinical Epidemiology, Biostatistics and Cancer Registry, Rionero in Vulture,
Italy; 15Cancer Registry and Histopathology Unit, ‘Civile M.P.Arezzo’ Hospital, Ragusa, Italy; 16Center for Cancer Prevention (CPO-Piemonte) and Human
Genetic Foundation, Torino, Italy; 17National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; 18Department of
Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands; 19Julius Center for Health Sciences and Primary Care,
University Medical Center Utrecht, Utrecht, The Netherlands; 20Public Health and Participation Directorate, Health and Health Care Services Council, Asturias,
Spain; 21Unit of Nutrition, Environment and Cancer, Catalan Institute of Oncology, Barcelona, Spain; 22Andalusian School of Public Health, Granada, Spain;
23CIBER Epidemiologı´a y Salud Pu´blica (CIBERESP), Spain; 24Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain; 25Navarra Public
Health Institute, Pamplona, Spain; 26Public Health Department of Gipuzkoa, Basque Government, San Sebastian, Spain; 27Center for Molecular Pathology,
Ska˚ne University Hospital, Lund University, Malmo¨, Sweden; 28Department of Surgery, Ska˚ne University Hospital, Lund University, Malmo¨, Sweden;
29Department of Clinical Sciences, Obstetrics and Gynecology, Umea˚ University, Umea˚, Sweden; 30Department of Public Health and Clinical Medicine, Umea˚
University, Umea˚, Sweden; 31Department of Medical Biosciences, Pathology, Umea˚ University, Umea˚, Sweden; 32Clinical Gerontology Unit, University of
Cambridge, Cambridge, UK; 33Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK; 34Department of Epidemiology and
Biostatistics, School of Public Health, Imperial College, London, UK
BACKGROUND: It is well established that parity and use of oral contraceptives reduce the risk of ovarian cancer, but the associations
with other reproductive variables are less clear.
METHODS: We examined the associations of oral contraceptive use and reproductive factors with ovarian cancer risk in the European
Prospective Investigation into Cancer and Nutrition. Among 327 396 eligible women, 878 developed ovarian cancer over an average of
9 years. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard models stratified by centre
and age, and adjusted for smoking status, body mass index, unilateral ovariectomy, simple hysterectomy, menopausal hormone therapy,
and mutually adjusted for age at menarche, age at menopause, number of full-term pregnancies and duration of oral contraceptive use.
RESULTS: Women who used oral contraceptives for 10 or more years had a significant 45% (HR, 0.55; 95% CI, 0.41–0.75) lower risk
compared with users of 1 year or less (P-trend,o0.01). Compared with nulliparous women, parous women had a 29% (HR, 0.71; 95%
CI, 0.59–0.87) lower risk, with an 8% reduction in risk for each additional pregnancy. A high age at menopause was associated with a
higher risk of ovarian cancer (452 vs p45 years: HR, 1.46; 95% CI, 1.06–1.99; P-trend, 0.02). Age at menarche, age at first full-term
pregnancy, incomplete pregnancies and breastfeeding were not associated with risk.
CONCLUSION: This study shows a strong protective association of oral contraceptives and parity with ovarian cancer risk, a higher risk with a
late age at menopause, and no association with other reproductive factors.
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In developed countries, ovarian cancer is the sixth most common
malignancy and cause of cancer death in women (American
Cancer Society, 2007). Some reproductive factors are associated
with the risk of ovarian cancer, with evidence for a protective
association of high parity and oral contraceptive use (Negri et al,
1991; Whittemore et al, 1992; Hankinson et al, 1995; Beral et al,
2008). However, the evidence that other reproductive variables,
such as breastfeeding, incomplete pregnancies, age at menarche
and age at menopause, are associated with risk is weak
and inconsistent, and mostly comes from case–control studies
(Riman et al, 2004).
The aim of this study was to evaluate the association between
oral contraceptive use and reproductive factors with ovarian
cancer risk in a large prospective European study. A secondary aim
was to examine whether these associations differed by participant
characteristics such as age at enrolment, body mass index (BMI)
and other factors.
MATERIALS AND METHODS
Source and study population
The European Prospective Investigation into Cancer and Nutrition
(EPIC) includes approximately 370 000 women and 150 000 men
and was designed to investigate dietary and lifestyle determinants
of cancer. The participants were recruited between 1992 and 2000
in 23 centres in 10 European countries (Denmark, France,
Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden
and the United Kingdom). The cohort population and data
collection procedures have been described in detail elsewhere
(Riboli et al, 2002). Approval for the study was obtained from
the local ethics committees in the participating countries and the
internal review board of the International Agency for Research on
Cancer.
Incident cancer cases were identified through linkage to
population cancer registries in Denmark, Italy, The Netherlands,
Norway, Spain, Sweden and the UK, or using a combination of
methods including linkage to health insurance records, cancer and
pathology registries, and active follow-up of study participants or
their next of kin in France, Germany and Greece.
Of the approximately 370 000 women enrolled in the cohort,
women were excluded if they had prevalent cancer (n¼ 19 707), if
they had incomplete follow-up data (n¼ 2205), if they had a
bilateral ovariectomy (n¼ 10 500), if they did not return the
baseline questionnaire (n¼ 509), if they never menstruated
(n¼ 61), if they had missing information on oral contraceptive
use and all reproductive history variables (n¼ 7589), or if they
were diagnosed with a non-epithelial ovarian cancer (n¼ 26). Of
the final analytic cohort of 327 396 women, 878 developed
epithelial ovarian cancer from the date of recruitment until the
end of follow-up (31 December 2003 to 20 December 2006,
according to centre). The cancer diagnosis was confirmed by
histology for 77.6% of the cases, by clinical examination for 13.8%
and the remaining 8.6% by self-report, autopsy or death certificate.
In all, 47% of tumours were of a serous histology, 10% were
mucinous, 10% endometrioid, 4% clear cell and 1% undiffer-
entiated; the remaining 28% had missing, undefined or not
otherwise specified histologies. Of the 878 cases, 70 were of low
malignant potential (borderline tumours); exclusion of these cases
did not change the risk estimates, and they were therefore included
in the final analysis.
Exposure and covariate assessment
Women were asked at the baseline questionnaire whether they had
ever used oral contraceptives, their duration of use up until the
time of recruitment, and the age at first use. Information on age at
menarche and menopause, numbers of full-term pregnancies
(defined as the sum of live and stillbirths), incomplete pregnancies
(defined as induced or spontaneous abortions) and age at the first
full-term pregnancy was also collected. Information on breastfeed-
ing was collected for the first three full-term pregnancies and
the last one. The duration of breastfeeding was calculated as the
sum for all pregnancies for which we had information. For women
with more than four pregnancies and who had breastfed for all the
pregnancies for which we had information, the duration of
breastfeeding was taken to be the number of pregnancies
multiplied by the mean of breastfeeding duration of each child.
Menopausal status was defined according to information on
menstruation status, hysterectomy, ovariectomy, use of exo-
genous hormones and age, details of which are provided elsewhere
(Dossus et al, 2010). The cumulative duration of menstrual cycles
among postmenopausal women was defined as the time between
age at menarche and age at menopause minus the cumulative
duration of full-term pregnancies (calculated as the number of full-
term pregnancies times 0.75) and oral contraceptive use.
Information on anthropometric data, physical activity, smoking
status, education level, self-reported diabetes mellitus, simple
hysterectomy (with ovarian conservation) and unilateral ovariect-
omy status was also collected from the baseline questionnaire.
Weight and height were measured at recruitment, except for part
of the Oxford cohort, the Norwegian cohort, and approximately
two-thirds of the French cohort, among whom weight and height
were self-reported. Body mass index was calculated as weight in
kilograms divided by height in metres squared. A combined
physical activity index was calculated, which incorporated
occupational and recreational activities.
Statistical analysis
Hazard ratios (HRs) and their 95% confidence intervals (CIs) for
ovarian cancer were estimated using Cox proportional hazards
models with age as the underlying time scale. Entry and exit time
was defined as the woman’s age at recruitment and age at ovarian
cancer diagnosis or censoring (death, lost to follow-up or end of
follow-up), respectively. All models were stratified by EPIC
recruitment centre and age at enrolment (p50, 51 –53, 54 –56,
57–59, 60–62, 63 –65,465 years). The proportionality of hazards
was verified based on the slope of the Schoenfeld residuals over
time, which is equivalent to testing that the log HR function is
constant over time (Schoenfeld, 1982). Linear trends were tested by
entering appropriate ordinal variables into the model, the
coefficients of which were evaluated by the Wald test.
All models were adjusted for potential risk factors for ovarian
cancer, including tobacco smoking status (never, former, current),
BMI (continuous), unilateral ovariectomy (no, yes), simple
hysterectomy (no, yes), menopausal hormone therapy (never,
former, current use: oestrogen only, oestrogen plus progestin,
other formulation), and further mutually adjusted for age at
menarche (o12, 12, 13, 14, X15 years), age at menopause
(premenopausal, perimenopausal, postmenopausal: p45, 46 –50,
51–52, 452 years; based on fourths of the distribution in the
controls), number of full-term pregnancies (0, 1, 2, 3, X4) and
duration of oral contraceptive use (never, ever: p1, 2 –4, 5– 9,
X10 years), as applicable. Only the fully adjusted statistical models
are presented in the text, because the centre and age-stratified
models yielded almost identical estimates. For each covariate,
missing values were assigned to separate categories, where
appropriate; an analysis that excluded individuals with missing
values for these covariates produced similar results and is not
presented here. Further adjustments for physical activity, diabetes
mellitus and education yielded almost identical results and are not
presented.
To examine whether the oestrogen dose in oral contraceptive
formulations influenced the risk, the analyses were stratified by
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calendar year of first oral contraceptive use. The oral contra-
ceptives prescribed before 1970 were typically high-dose prepara-
tions, whereas those prescribed between 1970 and 1980 were
typically medium dose and by 1980 most prescriptions were for
low-dose preparations (Piper and Kennedy, 1987; Thorogood and
Villard-Mackintosh, 1993).
Analyses were also performed by ovarian cancer histology,
EPIC-participating country and according to other factors includ-
ing: age at recruitment (at the median, o50 vs X50), BMI (at the
median, o24 vs X24 kg m2), smoking status (ever vs never),
parity (parous vs nulliparous), menopausal status (postmenopau-
sal vs pre/perimenopausal) and menopausal hormone therapy at
recruitment (ever vs never use and current vs never use). Tests for
interaction were carried out by using the relevant exposure
variables, indicator variables for the potentially modifying factors,
and product terms of the two variables. Sensitivity analyses were
run after excluding ovarian cancer cases that developed in the first
2 years of follow-up or after excluding participants with a history
of simple hysterectomy and/or unilateral ovariectomy at baseline.
The statistical significance of the interaction terms was evaluated
by the Wald test. All P-values (P) were two-sided and all analyses
were performed using STATA version 11 (College Station,
TX, USA).
RESULTS
After recruitment into the study, 878 cases of ovarian cancer were
diagnosed during 2.9 million person-years of follow-up, over an
average of 9 years (Table 1). The mean age at recruitment and
diagnosis for the ovarian cancer cases was 55 and 60 years,
respectively. In all, 59% of the cohort reported ever use of oral
contraceptives (Table 1), 9% of which were current users. Ever use
of oral contraceptive was lowest in Greece (10%) and highest in
Germany (82%). The median duration of oral contraceptive use
was 5 years but women in Greece, Italy and Spain had considerably
shorter durations. Eighty percent of the cohort reported having
had a full-term pregnancy, 28% reported ever having an
incomplete pregnancy and 82% reported that they had ever
breastfed. The overall mean ages at menarche and menopause
were 13 and 50 years, respectively, without any notable variation
by country.
Oral contraceptive use
Compared with never users of oral contraceptives, ever users had a
significantly lower risk of ovarian cancer in the age and centre-
stratified model (HR, 0.84; 95% CI, 0.72–0.98), and that remained
very similar after additional adjustment for smoking status, BMI,
unilateral ovariectomy, simple hysterectomy, menopausal hor-
mone therapy, age at menarche, age at menopause and number of
full-term pregnancies (HR, 0.86; 95% CI, 0.73– 1.00; Table 2).
Increasing duration of oral contraceptive use was associated with a
progressive reduction in risk; women who used oral contraceptives
for 10 or more years had a 45% (HR, 0.55; 95% CI, 0.41–0.75)
lower risk compared with users of 1 year or less, which
corresponded to a 13% (HR, 0.87; 95% CI, 0.82–0.93) lower risk
per 5 years of use (P-trend, o0.01). There was no association
between age at first use of oral contraceptives and risk of ovarian
cancer (Table 2), either before or after adjusting for duration of
oral contraceptive use (data not shown).
The reduced risk of ovarian cancer associated with ever use of
oral contraceptives was similar within each category of calendar
year of first use (1960s or earlier: HR, 0.83; 95% CI, 0.68–1.01;
1970s: HR, 0.80; 95% CI, 0.63–1.01; 1980s or later: HR, 0.90; 95%
CI, 0.69–1.16). The risk associated with increasing duration of oral
contraceptive use did not vary significantly by ovarian cancer
histology, country, age at recruitment, smoking status or parity
(data not shown). However, there was some evidence that this
association varied by BMI (Table 3; P-interaction, 0.01), with a
stronger inverse association in women with a BMI o24 kg m2
(X10 vs p1 year of use: HR, 0.38; 95% CI, 0.25–0.59; P-trend,
o0.01) compared with women with a BMI of 24 kg m2 or more
(HR, 0.80; 95% CI, 0.52– 1.23; P-trend, 0.24). This association was
also stronger in pre/perimenopausal women (Table 3; X10 vs p1
years of use: HR, 0.41; 95% CI, 0.26–0.63; P-trend,o0.01) than in
postmenopausal women (HR, 0.76; 95% CI, 0.49– 1.17; P-trend,
0.14; P-interaction, 0.02).
Parity and other reproductive variables
Compared with nulliparous women, women who had children had
a 29% (HR, 0.71; 95% CI, 0.59–0.87) lower risk of ovarian cancer
(Table 4), with a progressive reduction in risk with each additional
pregnancy. Compared with women with one full-term pregnancy,
women with four or more full-term pregnancies had a 23% lower
risk (HR, 0.77; 95% CI, 0.57–1.04), which corresponded to an 8%
(HR, 0.92; 95% CI, 0.85– 0.99) lower risk per full-term pregnancy
(P-trend, 0.03). Compared with nulliparous women, women with
four or more full-term pregnancies had a 38% lower risk (HR, 0.62;
95% CI, 0.46–0.83; P-trend, o0.01). Age at first full-term
pregnancy, ever having had an incomplete pregnancy and
breastfeeding were not associated with risk (Table 4).
The risk of ovarian cancer was not associated with age
at menarche or menopausal status (Table 4), although age at
menopause was significantly positively associated with risk (452
vs p45 years: HR, 1.46; 95% CI, 1.06– 1.99). The estimated
cumulative duration of menstrual cycles was also associated with a
higher risk (436 vs p27 years: HR, 1.57; 95% CI, 1.16–2.13;
P-trend, o0.01). A one-year increase in menstrual lifespan
corresponded to a 2% higher risk (HR, 1.02; 95% CI, 1.01–1.04).
However, when women who were diagnosed with ovarian cancer
within the first 2 years of follow-up were excluded from the analysis
(194 cases), the associations of age at menopause (452 vs p45
years: HR, 1.40; 95% CI, 0.98–2.00; P-trend, 0.12) and menstrual
lifespan (436 vsp27 years: HR, 1.37; 95% CI, 0.98–1.93; P-trend,
0.01) with risk of ovarian cancer were attenuated.
None of the associations between reproductive factors and risk
of ovarian cancer differed by ovarian cancer histology, country,
age, BMI, smoking status, menopausal status or menopausal
hormone therapy (data not shown). In addition, sensitivity
analyses that excluded participants with a history of simple
hysterectomy and/or unilateral ovariectomy at recruitment yielded
almost identical estimates.
DISCUSSION
This large prospective study confirms the strong protective
association of oral contraceptive use and parity on risk of ovarian
cancer. No significant associations with risk were found for age at
menarche, age at first full-term pregnancy, incomplete pregnancies
or breastfeeding.
There is strong evidence that oral contraceptive use reduces
ovarian cancer risk; a collaborative pooled analysis of 45
epidemiological studies (13 prospective and 32 case–control
studies) reported a relative risk of 0.73 (95% CI, 0.70–0.76) for
ever vs never users of oral contraceptives (Beral et al, 2008). That
study also showed a progressive decline with increasing duration
of use (10–14 years vso1 year: HR, 0.56; 95% CI, 0.50–0.62) of a
magnitude similar to our findings. The pooled analysis also
showed that, although the risk is attenuated with increasing time
since last use, the protective effect of oral contraceptives
on ovarian cancer remains for many years after cessation of use
(Beral et al, 2008). However, we were unable to examine this
association because many EPIC centres did not collect information
Reproductive factors and ovarian cancer
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on the age at last oral contraceptive use, and it is possible that the
stronger inverse associations observed for the duration of oral
contraceptive use and ovarian cancer risk among lean and
pre/perimenopausal women in our study population might, in
part, reflect a shorter time since last use among these women. Our
results also suggest that the dose of oestrogen contained in oral
contraceptives has a negligible impact on the association with
ovarian cancer risk, as shown by similar estimates in risk
according to calendar year of first oral contraceptive use, and
which is consistent with the findings from the pooled analysis
(Beral et al, 2008).
A protective as sociation between parity and ovarian cancer risk
has been observed in most previous studies (Negri et al, 1991;
Whittemore et al, 1992; Hankinson et al, 1995; Vachon et al, 2002;
Tung et al, 2003; Moorman et al, 2009). The current study suggests
that there is a quite large reduction in risk with the first child, with
progressive lower risks with each additional full-term pregnancy.
Our finding of no association between age at first full-term
pregnancy and ovarian cancer risk is consistent with most studies
(Kvale et al, 1988; Booth et al, 1989; Gwinn et al, 1990; Risch et al,
1994; Hankinson et al, 1995; Purdie et al, 1995; Riman et al, 2002;
Vachon et al, 2002; Braem et al, 2010), although some have
reported a reduction in risk with an early age at first full-term
pregnancy (Adami et al, 1994; Albrektsen et al, 1996; Mogren et al,
2001; Titus-Ernstoff et al, 2001; Whiteman et al, 2003; Pike et al,
2004). Our finding of no association between number of
incomplete pregnancies and ovarian cancer risk is consistent with
some studies (Kvale et al, 1988; Booth et al, 1989; Risch et al, 1994;
Purdie et al, 1995; Titus-Ernstoff et al, 2001), although others have
found a reduced risk with more incomplete pregnancies, but
Table 1 Participant characteristics at recruitment among women in the EPIC cohort by country, means or medians (s.d. or inter-quartile ranges) and
percentages
Characteristic
All
(n¼ 327 396)
Denmark
(n¼ 27 958)
France
(n¼ 67 504)
Germany
(n¼ 27 586)
Greece
(n¼ 14 459)
Italy
(n¼ 29 857)
Netherlands
(n¼ 26 259)
Norway
(n¼ 35 800)
Spain
(n¼ 23 975)
Sweden
(n¼ 20 418)
UK
(n¼ 53 580)
Number of cases 878 92 192 56 32 73 64 76 52 87 154
Age at recruitment, years 50.4 (9.7) 56.2 (4.4) 52.1 (6.6) 48.3 (8.9) 52.4 (12.6) 49.9 (8.1) 50.1 (11.7) 47.6 (4.3) 47.5 (8.4) 55.3 (8.0) 47.3 (14.4)
Body mass index (kgm2) 24.9 (4.4) 25.6 (4.4) 23.0 (3.4) 25.6 (4.7) 28.5 (5.2) 25.6 (4.3) 25.1 (4.2) 24.4 (3.8) 28.1 (4.7) 25.1 (4.2) 24.2 (4.2)
Current smokers (%) 19.7 31.4 8.8 18.6 17.5 26.3 28.0 31.7 19.4 24.6 11.0
Unilateral ovariectomy (%)
Yes 3.4 6.0 3.5 5.2 1.8 4.3 5.6 NR 2.9 NR 3.1
No 77.7 92.9 91.9 94.7 97.8 95.3 92.5 NR 97.0 NR 93.5
Missing 18.9 1.1 4.6 0.1 0.4 0.4 1.9 NR 0.1 NR 3.4
Hysterectomy (%)
Yes 7.9 11.4 7.6 12.5 3.1 5.5 15.3 4.7 3.3 NR 10.0
No 82.6 88.5 89.6 87.5 96.9 94.3 84.6 70.9 96.6 NR 88.7
Missing 9.5 0.1 2.8 0 0 0.2 0.1 24.4 0.1 NR 1.3
Oral contraceptive use (%)
Ever 58.9 58.2 61.6 81.7 9.8 41.4 73.8 64.1 42.9 51.1 66.5
Never 40.6 40.8 38.2 18.2 90.2 58.4 26.1 35.9 57.0 48.2 32.0
Missing 0.5 1.0 0.2 0.1 0 0.2 0.1 0 0.1 0.7 1.5
Duration (years) of OC usea 5 (2 – 10) 6 (2 – 12) 5 (2 – 10) 10 (5 – 30) 1 (1 – 3) 2 (1 – 5) 10 (5 – 15) 3 (1 – 7) 2 (1 – 5) 7 (3 – 14) 6 (3 – 10)
Age at first OC use (years)a 25.4 (6.7) 27.7 (5.7) 28.6 (6.5) NR 26.5 (6.0) 28.3 (6.8) 25.6 (7.3) 22.4 (4.1) NR 26.5 (7.3) 22.0 (5.8)
FTP (%)b
Ever 79.6 88.3 83.7 85.4 89.5 86.9 48.7 91.5 88.6 78.9 66.9
Never 13.6 11.4 8.8 14.4 10.3 13.1 6.9 8.5 10.5 9.1 31.3
Missing 6.8 0.3 7.5 0.2 0.2 0 44.4 0 0.9 12.0 1.8
Number of FTPc 2.3 (1.0) 2.2 (0.9) 2.3 (0.9) 2.0 (0.9) 2.4 (1.1) 2.1 (0.9) 2.7 (1.3) 2.4 (0.9) 2.7 (1.3) 2.2 (1.0) 2.3 (1.0)
Age at first FTP (years)c 24.9 (4.4) 23.8 (4.2) 24.9 (4.0) 24.3 (4.4) 24.2 (4.7) 25.8 (4.3) 25.6 (4.0) 24.1 (4.5) 24.7 (3.9) 24.7 (4.6) 26.0 (4.7)
Incomplete pregnancy (%)d
Ever 27.7 40.7 35.6 37.0 58.2 36.8 14.6 NR 24.6 15.9 23.4
Never 44.1 50.7 49.9 51.8 35.0 53.0 34.7 NR 65.0 54.2 47.6
Missing 28.2 8.6 14.5 11.2 6.8 10.2 50.7 NR 10.4 29.9 29.0
Breastfeeding (%)c
Ever 81.8 91.7 69.5 84.4 87.3 83.5 81.0 92.8 88.7 69.6 80.7
Never 14.7 6.8 27.9 15.3 11.3 16.0 18.4 5.7 10.8 3.6 13.7
Missing 3.5 1.5 2.6 0.3 1.4 0.5 0.6 1.5 0.5 26.8 5.6
Breastfeeding duratione 6 (3 – 13) 7 (4 – 12) 5 (2 – 7) 3 (1 – 8) 11 (4 – 24) 7 (3 – 12) 5 (2 – 9) 12 (6 – 19) 9 (4 – 16) 8 (4 – 13) 7 (2 – 15)
Age at menarche (years) 13.1 (1.5) 13.7 (1.6) 12.9 (1.4) 13.2 (1.5) 13.2 (1.7) 12.6 (1.5) 13.3 (1.6) 13.3 (1.4) 12.9 (1.6) 13.5 (1.5) 12.9 (1.6)
Age at menopause (years)f 50 (46 – 52) 50 (47 – 52) 50 (48 – 53) 50 (46 – 52) 49 (45 – 52) 50 (47 – 52) 50 (46 – 52) 48 (46 – 50) 50 (46 – 52) 50 (47 – 52) 50 (45 – 52)
Menopausal status (%)
Premenopausal 35.2 7.6 26.9 47.9 38.8 40.9 34.3 35.3 56.6 7.2 50.7
Perimenopausal 19.3 19.4 26.1 13.3 7.2 16.1 18.2 35.3 9.8 25.7 10.6
Postmenopausal 45.5 73.0 47.0 38.8 54.0 43.0 47.5 29.4 33.6 67.1 38.7
Total menstrual lifespang 33 (27 – 37) 32 (25 – 36) 35 (30 – 38) 30 (22 – 35) 33 (29 – 37) 35 (31 – 38) 30 (23 – 35) 32 (28 – 35) 33 (30 – 36) 33 (27 – 36) 33 (27 – 37)
Abbreviations: EPIC¼ European Prospective Investigation into Cancer and Nutrition; FTP¼ full-term pregnancy; NR¼ not reported; OC¼ oral contraceptive. aAmong ever OC
users only. bA FTP is defined as a live or stillbirth. cAmong women with a FTP only. dAn incomplete pregnancy is defined as an induced or spontaneous abortion. eAmong women
with a FTP who ever breastfed only; in months. fAmong postmenopausal women only. gCalculated in years as (age at menopause– age at menarche–duration of OC use–
cumulative duration of FTP) in postmenopausal women only.
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smaller in magnitude than the reduction observed for full-term
pregnancies (Negri et al, 1991; Whittemore et al, 1992; Riman et al,
2002; Pike et al, 2004; Zhang et al, 2004).
Breastfeeding was not significantly associated with ovarian
cancer risk in this study population, and although this is consistent
with several studies (Booth et al, 1989; Purdie et al, 1995;
Titus-Ernstoff et al, 2001; Riman et al, 2002; Pike et al, 2004), the
cumulative duration of breastfeeding was relatively short in our
study (upper category: 413 months), and we cannot rule out the
possibility of a protective association with a longer duration
(e.g., 418 or 424 months) as seen in some other studies
(Gwinn et al, 1990; Whittemore et al, 1992; Danforth et al, 2007;
Jordan et al, 2010). The association between age at menarche and
menopause and the risk of ovarian cancer has been extensively
studied, although the findings have generally been weak and
not statistically significant (Kvale et al, 1988; Gwinn et al, 1990;
Whittemore et al, 1992; Hankinson et al, 1995; Purdie et al,
1995; Schildkraut et al, 2001; Titus-Ernstoff et al, 2001; Riman
et al, 2002; Pike et al, 2004; Jordan et al, 2005; Braem et al, 2010).
The current study shows that although there is no association
between age at menarche and risk, a late age at menopause and the
cumulative duration of menstrual cycles are both positively
associated with ovarian cancer risk. If the number of menstrual
cycles is important in the development of ovarian cancer, as has
been suggested (Pike et al, 2004), it is likely that a difference of 1 or
2 years in the age at menarche will not contribute sufficiently to the
lifetime number of menstrual cycles compared with larger
differences in age at menopause, parity and oral contraceptive
use. However, the increased risk in ovarian cancer observed with
age at menopause was restricted to women in the highest category
(52 years or older), and it is possible that this increased risk is
partially a result of reverse causation, whereby older women may
mistake bleeding from a sub-clinical cancer as menses. Indeed,
after excluding the first 2 years of follow-up, the risk associated
with a relatively late age at menopause was slightly attenuated and
no longer statistically significant.
The exact mechanisms through which oral contraceptives and
parity may reduce risk are not known, although several hypotheses
have been proposed. These include inhibition of ovulation
(Fathalla , 1971), exposure to low concentrations of gonadotropins
(Stadel, 1975; Cramer and Welch, 1983), reduced retrograde
transportation of contaminants from the vagina or growth factors
from the uterus (Harlow et al, 1992; Cramer and Xu, 1995) and
exposure to high progesterone concentrations (Risch, 1998; Lau
et al, 1999; Syed et al, 2001; Riman et al, 2004; Mukherjee et al,
2005). In particular, pregnancy leads to anovulation, reduces
gonadotropin secretion, increases progesterone levels and tem-
porarily interrupts the retrograde transportation. Similarly,
combined oral contraceptives suppress the midcycle gonadotropin
surge with a consequent inhibition of ovulation. The increase in
risk with a late age at menopause supports the incessant ovulation
and the retrograde transportation hypotheses, but is not readily
compatible with the gonadotropin stimulation and progesterone
deficiency hypotheses (Riman et al, 2002).
Table 2 HR and 95% CI for oral contraceptive use and ovarian cancer
risk in the EPIC cohort
Variable
Cases/
non-cases
Age- and
centre-
stratified
HR (95% CI)
Multivariable-
adjusted
HR (95% CI)a
OC use
Never 453/132 622 1.00 (ref.) 1.00 (ref.)
Ever 418/192 401 0.84 (0.72–0.98) 0.86 (0.73–1.00)
Duration of OC use, yearsb
p1 96/35 185 1.00 (ref.) 1.00 (ref.)
2–4 109/41 341 1.04 (0.78–1.37) 1.05 (0.79–1.38)
5–9 83/41 723 0.79 (0.59–1.07) 0.80 (0.59–1.08)
X10 90/57 246 0.56 (0.42–0.76) 0.55 (0.41–0.75)
P-trend o0.01 o0.01
Per 5 years 0.88 (0.82–0.94) 0.87 (0.82–0.93)
Age at first OC useb
o25 115/75 496 1.00 (ref.) 1.00 (ref.)
25–29 81/34 282 1.03 (0.75–1.42) 1.04 (0.76–1.44)
30–34 73/20 495 1.34 (0.92–1.94) 1.36 (0.94–1.97)
X35 55/15 838 1.21 (0.78–1.87) 1.20 (0.78–1.86)
P-trend 0.23 0.23
Abbreviations: CI¼ confidence interval; EPIC¼ European Prospective Investigation
into Cancer and Nutrition; HR¼ hazard ratio; OC¼ oral contraceptive; ref.¼
reference. aFrom a Cox proportional hazards model stratified by EPIC-participating
centre and age at recruitment, and adjusted for smoking status (never, former,
current), body mass index (kgm2, continuous), unilateral ovariectomy (no, yes),
simple hysterectomy (no, yes), menopausal hormone therapy (never, former, current
use: oestrogen-only, oestrogen plus progestin, other formulation), age at menarche
(o12, 12, 13, 14, X15 years), number of full-term pregnancies (0, 1, 2, 3, X4) and
age at menopause (premenopausal, perimenopausal, postmenopausal:p45, 46–50,
51–52, 452 years). bAmong ever OC users only.
Table 3 HR and 95% CI for duration of oral contraceptive use and ovarian cancer risk by BMI and menopausal status in the EPIC cohort
BMI o24 kg m2 BMI X24 kg m2 Pre/perimenopausal Postmenopausal
Variable
Cases/
non-cases
HR
(95% CI)a
Cases/
non-cases
HR
(95% CI)a
Cases/
non-cases
HR
(95% CI)b
Cases/
non-cases
HR
(95% CI)b
Duration of OC use, yearsc
p1 52/17 673 1.00 (ref.) 44/17 512 1.00 (ref.) 54/22 645 1.00 (ref.) 42/12 540 1.00 (ref.)
2–4 58/22 652 0.93 (0.63–1.36) 51/18 689 1.19 (0.79–1.79) 58/28 756 0.88 (0.60–1.28) 51/12 585 1.27 (0.84–1.92)
5–9 38/23 922 0.57 (0.37–0.87) 45/17 801 1.13 (0.73–1.74) 38/29 806 0.55 (0.36–0.85) 45/11 917 1.18 (0.77–1.81)
X10 39/30 969 0.38 (0.25–0.59) 51/26 277 0.80 (0.52–1.23) 41/37 013 0.41 (0.26–0.63) 49/20 233 0.76 (0.49–1.17)
P-trend o0.01 0.24 o0.01 0.14
P-interaction 0.01 0.02
Per 5 years 0.80 (0.71–0.89) 0.94 (0.86–1.02) 0.83 (0.75–0.92) 0.91 (0.84–1.00)
P-interaction (continuous) 0.02 0.13
Abbreviations: BMI¼ body mass index; CI¼ confidence interval; EPIC¼ European Prospective Investigation into Cancer and Nutrition; HR¼ hazard ratio; OC¼ oral
contraceptive; ref.¼ reference. aFrom a Cox proportional hazards model stratified by EPIC-participating centre and age at recruitment, and adjusted for smoking status (never,
former, current), unilateral ovariectomy (no, yes), simple hysterectomy (no, yes), menopausal hormone therapy (never, former, current use: oestrogen-only, oestrogen plus
progestin, other formulation), age at menarche (o12, 12, 13, 14, X15 years), number of full-term pregnancies (0, 1, 2, 3, X4) and age at menopause (premenopausal,
perimenopausal, postmenopausal:p45, 46–50, 51–52,452 years). bFrom a Cox proportional hazards model stratified by EPIC-participating centre and age at recruitment, and
adjusted for smoking status (never, former, current), body mass index (kgm2, continuous), unilateral ovariectomy (no, yes), simple hysterectomy (no, yes), age at menarche
(o12, 12, 13, 14, X15 years) and number of full-term pregnancies (0, 1, 2, 3, X4). cAmong ever OC users only.
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Strengths of the present study include its prospective design and
the wide distribution of oral contraceptive use and reproductive
variables in different European studies. However, although EPIC is
one of the largest studies to date to examine reproductive factors
with ovarian cancer risk, there was limited statistical power to
detect differences by histological subtypes of ovarian cancer.
All analyses were adjusted for potential risk factors of ovarian
cancer and further mutually adjusted for menstrual and repro-
ductive variables, and which made little difference to the risk
estimates suggesting that residual confounding is unlikely to
influence our results. In particular, we lacked information on tubal
ligation in EPIC but given the low prevalence of this procedure in
Europe (Riman et al, 2002), the extent of potential confounding
is expected to be minimal.
In conclusion, this study shows a strong protective association
of oral contraceptive use and parity with risk of ovarian cancer, a
higher risk with a late age at menopause, and no association with
other reproductive factors in this large cohort of European women.
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Table 4 HR and 95% CI for parity, other reproductive variables and
ovarian cancer risk in the EPIC cohort
Variable
Cases/
non-cases
Age- and centre-
stratified
HR (95% CI)
Multivariable-
adjusted
HR (95% CI)a
FTPb
Never 133/44 328 1.00 (ref.) 1.00 (ref.)
Ever 689/259 740 0.70 (0.58–0.85) 0.71 (0.59–0.87)
Number of FTP
Never 133/44 328 1.00 (ref.) 1.00 (ref.)
1 135/47 766 0.79 (0.62–1.01) 0.80 (0.63–1.02)
2 335/125 984 0.73 (0.59–0.89) 0.74 (0.61–0.91)
3 149/59 703 0.63 (0.49–0.80) 0.64 (0.50–0.81)
X4 70/26 287 0.61 (0.45–0.82) 0.62 (0.46–0.83)
P-trend o0.01 o0.01
Number of FTPc
1 135/47 766 1.00 (ref.) 1.00 (ref.)
2 335/125 984 0.93 (0.76–1.14) 0.94 (0.77–1.15)
3 149/59 703 0.80 (0.63–1.02) 0.81 (0.64–1.02)
X4 70/26 287 0.77 (0.57–1.04) 0.77 (0.57–1.04)
P-trend 0.03 0.03
Per FTP 0.92 (0.85–0.99) 0.92 (0.85–0.99)
Age at first FTP (years)c
p20 97/38 591 1.00 (ref.) 1.00 (ref.)
21–23 170/69 656 0.91 (0.71–1.17) 0.92 (0.72–1.19)
24–25 145/50 567 1.05 (0.81–1.36) 1.07 (0.82–1.39)
26–30 208/73 523 1.03 (0.80–1.31) 1.05 (0.81–1.34)
430 64/26 419 0.91 (0.66–1.26) 0.93 (0.67–1.29)
P-trend 0.79 0.69
Incomplete pregnancyd
Never 413/143 841 1.00 (ref.) 1.00 (ref.)
Ever 237/90 352 1.00 (0.85–1.18) 1.00 (0.85–1.18)
Breastfeedingc
Never 115/38 087 1.00 (ref.) 1.00 (ref.)
Ever 543/212 490 0.86 (0.69–1.06) 0.86 (0.70–1.07)
Duration of breastfeeding, monthsc
p1 (Including never) 176/58 968 1.00 (ref.) 1.00 (ref.)
2 –6 205/85 202 0.83 (0.68–1.02) 0.84 (0.68–1.03)
7 –12 134/50 185 0.90 (0.71–1.13) 0.91 (0.72–1.14)
413 139/54 475 0.87 (0.68–1.11) 0.88 (0.69–1.13)
P-trend 0.38 0.45
Age at menarche (years)
o12 145/48 285 1.00 (ref.) 1.00 (ref.)
12 159/69 012 0.75 (0.60–0.94) 0.76 (0.61–0.96)
13 208/83 793 0.77 (0.62–0.96) 0.79 (0.64–0.98)
14 192/70 040 0.79 (0.64–0.99) 0.82 (0.66–1.02)
X15 161/51 355 0.82 (0.65–1.04) 0.85 (0.68–1.08)
Table 4 (Continued )
Variable
Cases/
non-cases
Age- and centre-
stratified
HR (95% CI)
Multivariable-
adjusted
HR (95% CI)a
P-trend 0.29 0.46
Per year 1.00 (0.95–1.04) 1.00 (0.96–1.05)
Age at menopause (years)e
p45 75/23 730 1.00 (ref.) 1.00 (ref.)
46–50 172/46 885 1.14 (0.87–1.50) 1.12 (0.84–1.49)
51–52 75/19 790 1.11 (0.80–1.54) 1.08 (0.77–1.52)
452 120/22 831 1.51 (1.12–2.03) 1.46 (1.06–1.99)
P-trend o0.01 0.02
Per year 1.02 (1.00–1.05) 1.02 (1.00–1.05)
Menopausal status
Pre/perimenopausal 331/178 107 1.00 (ref.) 1.00 (ref.)
Postmenopausal 547/148 411 0.92 (0.73–1.16) 0.87 (0.69–1.10)
Total menstrual lifespan, yearsf
p27 75/25 330 1.00 (ref.) 1.00 (ref.)
28–32 71/22 627 1.05 (0.76–1.46) 1.07 (0.77–1.49)
33–36 121/28 006 1.42 (1.06–1.91) 1.44 (1.07–1.95)
436 135/27 225 1.56 (1.16–2.10) 1.57 (1.16–2.13)
P-trend o0.01 o0.01
Per year 1.02 (1.01–1.04) 1.02 (1.01–1.04)
Abbreviations: CI¼ confidence interval; EPIC¼ European Prospective Investigation
into Cancer and Nutrition; FTP¼ full-term pregnancy; HR¼ hazard ratio; ref.¼ re-
ference. aFrom a Cox proportional hazards model stratified by EPIC-participating
centre and age at recruitment, and adjusted for smoking status (never, former,
current), body mass index (kgm2, continuous), unilateral ovariectomy (no, yes),
simple hysterectomy (no, yes), menopausal hormone therapy (never, former, current
use: oestrogen-only, oestrogen plus progestin, other formulation), duration of oral
contraceptive use (never, ever:p1, 2–4, 5 –9, X10 years), age at menarche (o12,
12, 13, 14, X15 years) and age at menopause (premenopausal, perimenopausal,
postmenopausal: p45, 46–50, 51–52, 452 years). The models for incomplete
pregnancy, age at menarche and menopause were further adjusted for number of
FTPs (0, 1, 2, 3, X4). The model for menopausal status was not adjusted for
menopausal hormone therapy and age at menopause. The model for total menstrual
lifespan was not adjusted for age at menopause, age at menarche, duration of oral
contraceptive use and number of FTPs. bA FTP is defined as a live or stillbirth.
cAmong women with a FTP. dAn incomplete pregnancy is defined as an induced or
spontaneous abortion. eAmong postmenopausal women only. fCalculated as (age at
menopause– age at menarche–duration of oral contraceptive use– cumulative
duration of FTP) in postmenopausal women only.
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